Company intelligence / Profile preview
Pep2Tango Therapeutics
Potomac, Maryland, United States
- Ownership
- Private
- Employees
- ~15
- Development stage
- Other
01
Overview
Pep2Tango’s lead program is a first-in-class unimolecular tetra-receptor agonist peptide for obesity. Preclinical studies have shown superior weight loss compared to tirzepatide, with selective fat mass loss, muscle mass preservation, improved lipid profiles, better glycemic control, and beneficial liver effects. The company is preparing for IND submission in 2025 and has not yet entered clinical trials.[3][6]
- Therapeutic areas
- EndocrinologyCardiovascularNeurologyMetabolic Disorders
- Modalities
- Synthetic peptidesUnimolecular multi-receptor peptide agonists[1][3][4]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Versant Ventures (lead investor/backer)[8]
Beyond the preview
Go deeper on Pep2Tango Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pep2Tango Therapeutics.